Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.
ALNY Key Statistics
Stock Snapshot
As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $208.00. The company's market cap stands at 29.41B, with a P/E ratio of 68.10.
On 2026-07-31, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $197.81 and a high of $288.15. Shares are currently priced at $208.00, which is +5.2% above the low and -27.8% below the high.
Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 9.84M, against a daily average of 2.11M.
In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $197.81.
In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $197.81.
ALNY News
With inflation trends, growth signals and interest rate expectations shifting across major economies, many investors are looking for companies that analysts alr...
Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the Debt & Financing category. Unlock powerful investing tools with TipRanks Premium to make smarte...
Image source: The Motley Fool. Thursday, July 30, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Josh Brodsky Chief Executive O...
Analyst ratings
73%
of 30 ratingsMore ALNY News
Alnylam Pharmaceuticals ((ALNY)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing to...
The company reported second-quarter adjusted earnings of $1.84 per share, beating the consensus of $1.55. Sales jumped 67% year over year to $1.291 billion, mi...
(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) plunged after lowering its full-year TTR revenue guidance, overshadowing strong second-quarter revenue growth a...
Alnylam (ALNY) is down -27.8%, or -$79.74 to $206.88. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decision...
In early trading on Thursday, shares of Nebius Group topped the list of the day's best performing components of the Nasdaq 100 index, trading up 22.4%. Year to...
In July 2026, Alnylam Pharmaceuticals reported past progress on its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference, inclu...
Alnylam Pharmaceuticals (ALNY) is in focus after presenting new mivelsiran data and trial updates at the Alzheimer’s Association International Conference, spotl...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.